Interestingly, the combination therapy of ziv-aflibercept and pembrolizumab showed efficacy in anti-PD-1-resistant melanoma patients with ocular and mucosal disease, with a mean follow-up time of 20.6 months. Here, PDCD1 is linked to melanoma.